导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 23.74% | 181/4773 |
| 近一周 | -2.14% | 1313/5462 |
| 近一月 | 0.98% | 468/5421 |
| 近一季 | 1.31% | 554/5209 |
| 近半年 | -3.65% | 2278/4920 |
| 近一年 | 23.10% | 324/4366 |
| 近两年 | 35.10% | 2091/2954 |
| 近三年 | 21.66% | 1413/2253 |
| 成立以来 | 208.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
18.63% 22/4961 |
-12.52% 4411/5312 |
- - |
- - |
| 2025 | -5.50% 3374/4813 |
-10.35% 3440/3635 |
-2.14% 3317/4076 |
7.91% 3429/4524 |
-0.17% 2394/4813 |
| 2024 | 1.51% 2005/3463 |
7.46% 245/2808 |
-0.61% 797/3014 |
4.44% 2898/3129 |
-9.00% 2895/3463 |
| 2023 | 11.00% 80/2656 |
3.50% 1179/2280 |
-6.41% 1634/2385 |
10.09% 1/2515 |
4.09% 37/2655 |
| 2022 | 14.44% 7/2207 |
21.87% 1/1919 |
7.59% 449/2016 |
4.75% 2/2113 |
-16.68% 2082/2208 |
| 2021 | 50.19% 4/1822 |
3.48% 175/1255 |
20.32% 150/1330 |
42.02% 1/1466 |
-15.07% 1635/1822 |
| 2020 | - - |
- - |
2.51% 970/1067 |
15.49% 212/1164 |
19.53% 74/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国泰中证煤炭ETF VS. 长安沪深300非周期A(740101) |